Platelet activation and aggregation triggers

Platelet activation and aggregation triggers represent the diverse array of endogenous molecules and their corresponding receptors that drive the transition of platelets from a quiescent state to an active, pro-thrombotic state (NIH/NCBI, 2022). This complex biological process is initiated by primary agonists such as collagen, thrombin, adenosine diphosphate (ADP), and thromboxane A2 (TXA2), which interact with specific platelet surface receptors like Glycoprotein VI, Protease-activated receptors (PAR-1/4), and P2Y12 (Journal of Clinical Investigation, 2019). Activation leads to intracellular signaling cascades that result in degranulation, shape change, and the conformational activation of the integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor, which facilitates platelet-to-platelet bridging via fibrinogen (StatPearls, 2023). While these triggers are vital for normal hemostasis and wound repair, their pathological activation is a central driver of atherothrombosis, leading to clinical events such as myocardial infarction and ischemic stroke (PubMed, 2021). Therapeutic strategies focus on inhibiting these triggers or their downstream signaling to prevent thrombotic complications, with common agents including COX-1 inhibitors, P2Y12 receptor antagonists, and GPIIb/IIIa inhibitors (StatPearls, 2023).

Other names

Platelet agonistsHemostatic triggersThrombogenic stimuliProthrombotic factors

Inhibition of cyclooxygenase-1 (COX-1), antagonism of P2Y12 receptors, antagonism of protease-activated receptor-1 (PAR-1), and blockade of glycoprotein IIb/IIIa (GPIIb/IIIa) receptors.